SLS - CIK 0001390478
The table below shows SELLAS Life Sciences Group, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$28.39M | -$35.40M | -$31.41M | -$23.81M | -$26.02M | -$10.42M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | $0.00 | -$5.50M | -$4.50M | $0.00 | - |
| Dividends paid | - | - | - | - | - | - |
SELLAS Life Sciences Group, Inc. reported operating cash flow of -$28.39M for fiscal year 2025. That is up 19.8% from -$35.40M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$11.85M (FY 2016) to -$28.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $86.30M | $46.76M | $22.32M | $24.08M | $12.07M | $38.44M |